RIECKERMANN AT RDS SUMMIT IN CHINA 2026
Presenting end-to-end radiopharmaceutical solutions for industry advancements
Rieckermann was recently at the 3rd Global Radiopharmaceutical Development Conference (RDS), held from March 19 to 20, 2026 in Shanghai, China. They attended alongside partner TEMA SINERGIE, a long-established specialist in nuclear medicine technologies with decades of industry experience. Together, they showcased advanced technologies that support the safe, efficient development of next-generation radiopharmaceuticals.
Highlighting comprehensive radiopharmaceutical portfolio
Rieckermann presented a wide range of technologies and services designed to meet the stringent safety, regulatory, and efficiency requirements of radiopharmaceutical facilities, including:
- Synthesis & dispensing hot cells for safe and compliant handling of radioactive materials
- Dose calibrators and dispensing systems ensuring accuracy, traceability, and patient safety
- Radiopharmaceutical injectors that support precise and controlled administration
- Monitoring systems for real-time radiation safety, environmental control, and compliance
- Integrated turnkey support, from machinery provision to engineering design and project execution, as well as lifecycle service and maintenance
These solutions support the full radiopharmaceutical workflow, ranging from synthesis and quality control to dispensing and administration, enabling customers to optimize operations while ensuring patient and operator safety.
Delivering market and regulatory insights
In addition to the technology showcase, Rieckermann and TEMA SINERGIE engaged in in-depth discussions with conference participants on emerging trends, regulatory challenges, and the growing demand for scalable theragnostic infrastructure across Asia and beyond.
Rieckermann, particularly, played their role as a reliable solution partner for radiopharmaceutical manufacturers. With expert presence on site, they provided insights into how cutting-edge infrastructure and automation technologies can accelerate safe, compliant, and efficient radiopharmaceutical production.
A commitment towards growth and progress
Rieckermann’s participation reflects their continued investment in the rapidly growing radiopharmaceutical sector, particularly in Asia-Pacific. As the region’s demand for radiopharmaceutical production and clinical infrastructure grows, the company is committed to continue supporting industry players with tailored engineering solutions, global technology partnerships, and strong regional execution capabilities.
